Therapeutic Potential and Mechanisms of Mesenchymal Stem Cells in Coronary Artery Disease: Narrative Review
International Journal of Molecular Sciences · 05.06.2025 · 26 (11) · 5414
DOI: 10.3390/ijms26115414 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.06.2025. Verfasst von Tejas Patel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Apex Heart Institute, Ahmedabad 380059, India. Hauptthemen laut MEDLINE: Mesenchymal Stem Cell Transplantation, Coronary Artery Disease, Mesenchymal Stem Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Coronary artery disease (CAD) remains a leading cause of global morbidity and mortality despite advances in medical and interventional therapies. Mesenchymal stem cell (MSC) therapy has emerged as a promising regenerative approach for patients with refractory or non-revascularizable CAD. MSCs exhibit unique immunomodulatory, pro-angiogenic, and anti-fibrotic properties, primarily through paracrine mechanisms involving the secretion of cytokines, growth factors, and exosomal microRNAs. Clinical and preclinical studies have demonstrated improvements in myocardial perfusion, left ventricular ejection fraction (LVEF), and functional capacity following MSC-based interventions, particularly in patients with low baseline LVEF and heightened inflammation. Various MSC sources—including bone marrow, adipose tissue, and umbilical cord—offer distinct advantages, while delivery strategies such as intracoronary, intramyocardial, intravenous, and subcutaneous administration impact cell retention and efficacy. Advances in genetic modification, hypoxic preconditioning, and exosome-based therapies aim to enhance MSC survival and therapeutic potency. However, challenges persist regarding cell engraftment, cryopreservation effects, and inter-patient variability. Moving toward precision cell therapy, future approaches may involve stratifying patients by inflammatory status, ischemic burden, and comorbidities to optimize treatment outcomes. MSCs may not yet replace conventional therapies but are increasingly positioned to complement them within a personalized, regenerative framework for CAD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Apex Heart Institute, Ahmedabad 380059, India.
- St. Catherine Specialty Hospital, 10000 Zagreb, Croatia.
- Bonus BioGroup, Haifa 31905, Israel.
- School of Medicine, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
- Faculty of Science, Department of Molecular Biology, University of Zagreb, 10000 Zagreb, Croatia.
- Geisinger Commonwealth School of Medicine, Scranton, PA 18509, USA.
ORCID-Profile: Tejas Patel, Petar Brlek, Samir B Pancholy, Dragan Primorac
Zitieren
APA
Patel, T., Mešić, J., Meretzki, S., Bronshtein, T., Brlek, P., Kivity, V., Pancholy, S. B., Petrović, M., & Primorac, D. (2025). Therapeutic Potential and Mechanisms of Mesenchymal Stem Cells in Coronary Artery Disease: Narrative Review. International Journal of Molecular Sciences, 26(11), 5414. https://doi.org/10.3390/ijms26115414
Vancouver
Patel T, Mešić J, Meretzki S, Bronshtein T, Brlek P, Kivity V, et al. Therapeutic Potential and Mechanisms of Mesenchymal Stem Cells in Coronary Artery Disease: Narrative Review. International Journal of Molecular Sciences. 2025;26(11):5414. doi:10.3390/ijms26115414
BibTeX
@article{Patel2025,
author = {Patel, Tejas and Mešić, Jana and Meretzki, Shai and Bronshtein, Tomer and Brlek, Petar and Kivity, Vered and Pancholy, Samir B and Petrović, Matko and Primorac, Dragan},
title = {Therapeutic Potential and Mechanisms of Mesenchymal Stem Cells in Coronary Artery Disease: Narrative Review},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {11},
pages = {5414},
doi = {10.3390/ijms26115414}
}
EUVIMED